---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126216"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:54:34.682866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kyverna reports Q4/FY2025 results; cash $279M, SPS BLA on track for 1H 2026

## Summary
- Net loss $37.8M Q4, $161.3M FY2025; R&D $30.0M Q4, G&A $9.3M Q4.
- Cash and equivalents $279.3M; raised $147.5M in equity and $25M from loan facility.
- SPS registrational trial met primary endpoints; BLA submission expected 1H 2026; launch-ready by YE 2026.
- Phase 3 gMG trial enrolling; first patient Dec 2025; 14 sites active across three geographies.
- Positive PMS Phase 1 data: 83% (5/6) patients achieved EDSS improvement; no high-grade CRS/ICANS.

## SEC filing metadata
- accession: 0001193125-26-126216
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/0001193125-26-126216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/kytx-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126216
- JSON: https://secwatch.observer/filing/0001193125-26-126216.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126216.txt

## Key facts
- Earnings Releases
  Kyverna Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
  - Period: fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/0001193125-26-126216-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.